In the double-blind placebo-controlled Phase 3 TRANSFORM-1 study, the investigational agent (navitoclax) in combination with ruxolitinib will be compared to ruxolitinib with matching placebo, to evaluate its effect on splenomegaly, bone marrow fibrosis, anemia responses and quality of life.
- 18 years of age or older
- Have been diagnosed with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis
- Currently have Intermediate-2 or High-Risk myelofibrosis
- Have not received prior treatment with a JAK-2 inhibitor therapy
- Have splenomegaly of at least 5 cm